| Rising incidence and incidence-based mortality of thyroid cancer in California, 2000-2017 KL Yan, S Li, CH Tseng, J Kim, DT Nguyen, NB Dawood, MJ Livhits, ... The Journal of Clinical Endocrinology & Metabolism 105 (6), 1770-1777, 2020 | 60 | 2020 |
| Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival BM Ellingson, PY Wen, SM Chang, M van den Bent, MA Vogelbaum, G Li, ... Neuro-oncology 25 (6), 1017-1028, 2023 | 27 | 2023 |
| Bethesda III and IV thyroid nodules managed nonoperatively after molecular testing with Afirma GSC or Thyroseq v3 NE Kim, RS Raghunathan, EG Hughes, XR Longstaff, CH Tseng, S Li, ... The Journal of Clinical Endocrinology & Metabolism 108 (9), e698-e703, 2023 | 13 | 2023 |
| Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors L Sun, JC Kienzler, JG Reynoso, A Lee, E Shiuan, S Li, J Kim, L Ding, ... Journal of Clinical Investigation 133 (17), e169314, 2023 | 12 | 2023 |
| Efficient Algorithms and Implementation of a Semiparametric Joint Model for Longitudinal and Competing Risk Data: With Applications to Massive Biobank Data S Li, N Li, H Wang, J Zhou, H Zhou, G Li Computational and Mathematical Methods in Medicine 2022, 1-12, 2022 | 9 | 2022 |
| A flexible joint model for multiple longitudinal biomarkers and a time‐to‐event outcome: With applications to dynamic prediction using highly correlated biomarkers N Li, Y Liu, S Li, RM Elashoff, G Li Biometrical Journal 63 (8), 1575-1586, 2021 | 9 | 2021 |
| Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib D Ngo, J Tinajero, S Li, J Palmer, H Pourhassan, A Aribi, R Nakamura, ... Leukemia & Lymphoma 65 (3), 372-377, 2024 | 5 | 2024 |
| JMcmprsk: An R Package for Joint Modelling of Longitudinal and Survival Data with Competing Risks H Wang, N Li, S Li, G Li The R Journal 13 (1), 53--68, 2021 | 4 | 2021 |
| Diagnostic performance of molecular testing in indeterminate (Bethesda III and IV) thyroid nodules with Hürthle cell cytology R Raghunathan, XR Longstaff, EG Hughes, SJ Li, VR Sant, CH Tseng, ... Surgery, 2023 | 1 | 2023 |
| PDXpower: A Power Analysis Tool for Experimental Design in Pre-clinical Xenograft Studies for Uncensored and Censored Outcomes S Li, D Telesca, HI Kornblum, D Nathanson, F Pajonk, EH Cui, J Palmer, ... arXiv preprint arXiv:2404.08927, 2024 | | 2024 |
| Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high‐grade hepatotoxicity without adversely impacting outcomes J Tinajero, S Xu, D Ngo, S Li, J Palmer, T Nguyen, A Stein, P Koller, ... British Journal of Haematology, 2024 | | 2024 |
| Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia T Othman, S Li, J Zhang, H Pourhassan, V Agrawal, D Ngo, J Chen, ... American journal of hematology, 2024 | | 2024 |
| A joint model of the individual mean and within-subject variability of a longitudinal outcome with a competing risks time-to-event outcome S Li, DS Nuyujukian, RL McClelland, PD Reaven, J Zhou, H Zhou, G Li arXiv preprint arXiv:2301.06584, 2023 | | 2023 |
| Abstract B032: Immune landscape of resected brain metastases in patients treated with and without immune checkpoint blockade immunotherapy EF Shiuan, L Sun, J Reynoso, S Li, G Li, J Kim, W Kim, R Prins Cancer Research 83 (2_Supplement_2), B032-B032, 2023 | | 2023 |
| Interim results of a phase Ib single-center study of pembrolizumab in combination with chemotherapy in patients with locally advanced or metastatic small cell/neuroendocrine … AI Chin, A Drakaki, S Rodriguez, A Sachadeva, M Bradley, N Zomorodian, ... Journal of Clinical Oncology 40 (6_suppl), 510-510, 2022 | | 2022 |
